Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of CART22 Cells in Relapsed/Refractory B-cell ALL
NCT02588456Phase 1Terminated
- Sponsor
- University of Pennsylvania
- Start
- Oct 2015
- Primary completion
- Sep 2017
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CART22 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by University of Pennsylvania. Primary endpoint: Number of Adverse Events at 3 years. Started Oct 2015; status: terminated.
02
Drugs
CART22
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT02588456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02588456.